BioNTech’s Lung Cancer Breakthrough: A Turning Point for Oncology and Beyond BioNTech SE’s investigational lung cancer drug gotistobart has produced stunning results in its Phase 3 trial, nearly doubling survival rates compared to standard of care chemotherapy.
The overall survival benefit in patients with metastatic squamous non small cell lung cancer is clinically meaningful. This breakthrough extends far beyond the clinical data.
In recent years, a flood of new cancer treatments has emerged from Big Pharma’s research labs, but many have been met with lukewarm enthusiasm due to concerns about cost, efficacy, and accessibility.